Ledipasvir GS - 5885 CAS : 1256388-51-8 GMP DMF
Name : Ledipasvir
CAS No . : 1256388-51-8
Synonym : GS - 5885
Chemical Name : Methyl N- [ ( 2S ) - 1 - [ ( 6S ) - 6 - [ 5 - [ 9 , 9 - Difluoro - 7 - [ 2 - [ ( 1S , 2S , 4R ) - 3 - [ ( 2S ) - 2 - ( methoxycarbonylamino ) - 3-methylbutanoyl ] - 3 -
azabicyclo [ 2 . 2 .1 ] heptan - 2 - yl ] - 3H - benzimidazol - 5 - yl ] fluoren - 2 - yl ] - 1H - imidazol - 2 - yl ] - 5 - azaspiro [ 2 . 4 ] heptan - 5 - yl ] -
3 - methyl - 1 - oxobutan - 2 - yl ] carbamate
Molecular Formula : C49H54F2N8O6
Molecular Weight : 889
Ledipasvir developped by Gilead Sciences is used to treat Hepatitis
C. Ledipasvir is a inhibitor of a hepatitis C virus protein called
NS5A. It is used together with another drug called Sofosbuvir. The
fixed dose - combination tablet Ledipasvir / Sofosbuvir was
approved by US FDA in February 10 , 2014 . The brand name of the
combination product Ledipasvir / Sofosbuvir is Harvoni. It is used
for genotpye 1 Hepatitis C.
The drug might be protected by patents in some courtires or areas.
We only sell it to non patent protected countries or areas. The
sale to patent protection countries and areas is only for R & D
purpose. The buyers should take all responsiblity of patent status
in his countries or areas.
Competitive Advantage: Produced under cGMP conditions, support